MARKET

ADMA

ADMA

ADMA Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.460
-0.010
-0.40%
After Hours: 2.490 +0.03 +1.22% 19:57 01/26 EST
OPEN
2.560
PREV CLOSE
2.470
HIGH
2.570
LOW
2.445
VOLUME
4.35M
TURNOVER
--
52 WEEK HIGH
4.299
52 WEEK LOW
1.450
MARKET CAP
232.59M
P/E (TTM)
-2.8429
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-ADMA Biologics Says Centers For Medicare And Medicaid Services Issued A Permanent, Product-Specific J-Code For ASCENIV™
reuters.com · 16h ago
ADMA Biologics Receives Unique Permanent J-Code for ASCENIV
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today anno...
GlobeNewswire · 17h ago
Immunoglobulins Market 2021 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, Covid-19 Impact Analysis on Key Country Forecast to 2026
The Express Wire · 1d ago
Seeking Alpha Catalyst Watch
welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 4d ago
Hyperimmune Globulins Market Report Production and Demand Analysis 2021 to 2027
Jan 22, 2021 (Market Insight Reports) -- Global Hyperimmune Globulins Market trends analysis report 2021, the future of the industries is predicted on the...
Market Insight Reports · 4d ago
Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market | 2021 Healthcare Industry Analysis By COVID-19 Impact Forecast By Size, Growth, Share Estimation, Business, And Global Trends Analysis To 2026
Jan 21, 2021 (The Expresswire) -- Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market | 2021 COVID-19 Impact On Healthcare Industry Size,...
The Express Wire · 5d ago
Intravenous Immunoglobulin Market up-to-date Analysis of Industry Trends 2021- 2030 | Hualan Biological Engineering Inc, Omrix Biopharmaceuticals Ltd
Jan 21, 2021 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Intravenous Immunoglobulin market...
marketresearch.biz · 5d ago
ADMA Biologics (ADMA) Receives a Rating Update from a Top Analyst
SmarterAnalyst · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMA. Analyze the recent business situations of ADMA Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMA stock price target is 8.83 with a high estimate of 11.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 54.00M
% Owned: 57.11%
Shares Outstanding: 94.55M
TypeInstitutionsShares
Increased
24
3.03M
New
36
-470.67K
Decreased
40
5.60M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Independent Director
Steven Elms
President/Chief Executive Officer/Co-Founder/Director
Adam Grossman
Vice Chairman/Co-Founder/Director
Jerrold Grossman
Chief Financial Officer/Executive Vice President
Brian Lenz
Executive Vice President/Chief Scientific Officer
James Mond
Independent Director
Martha Demski
Independent Director
Bryant Fong
Independent Director
Lawrence Guiheen
  • Dividends
  • Splits
  • Insider Activity
No Data
About ADMA
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMA stock methods without spending real money on the virtual paper trading platform.